+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Fibrosis - Pipeline Insight, 2020

  • ID: 4989268
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 2
Pulmonary Fibrosis Overview

Pulmonary Fibrosis Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Pulmonary Fibrosis market. A detailed picture of the Pulmonary Fibrosis pipeline landscape is provided, which includes the disease overview and Pulmonary Fibrosis treatment guidelines. The assessment part of the report embraces in-depth Pulmonary Fibrosis commercial assessment and clinical assessment of the Pulmonary Fibrosis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Pulmonary Fibrosis of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Pulmonary Fibrosis treatment.
  • Pulmonary Fibrosis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Pulmonary Fibrosis Analytical Perspective

In-depth Pulmonary Fibrosis Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Pulmonary Fibrosis Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Pulmonary Fibrosis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Pulmonary Fibrosis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Pulmonary Fibrosis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Pulmonary Fibrosis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pulmonary Fibrosis .
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pulmonary Fibrosis .
  • In the coming years, the Pulmonary Fibrosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Pulmonary Fibrosis treatment market. Several potential therapies for Pulmonary Fibrosis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pulmonary Fibrosis market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Pulmonary Fibrosis ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Pulmonary Fibrosis treatment?
  • How many companies are developing therapies for the treatment of Pulmonary Fibrosis?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Pulmonary Fibrosis?
  • How many Pulmonary Fibrosis emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Pulmonary Fibrosis?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Pulmonary Fibrosis market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Pulmonary Fibrosis?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Pulmonary Fibrosis therapies?
  • What are the clinical studies going on for Pulmonary Fibrosis and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Pulmonary Fibrosis?
  • How many patents are granted and pending for the emerging therapies for the treatment of Pulmonary Fibrosis?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 2
1. Report Introduction

2. Pulmonary Fibrosis
2.1. Overview
2.2. History
2.3. Pulmonary Fibrosis Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Pulmonary Fibrosis Diagnosis
2.6.1. Diagnostic Guidelines

3. Pulmonary Fibrosis Current Treatment Patterns
3.1. Pulmonary Fibrosis Treatment Guidelines

4. Pulmonary Fibrosis - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Pulmonary Fibrosis companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Pulmonary Fibrosis Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Pulmonary Fibrosis Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Pulmonary Fibrosis Late Stage Products (Phase-III)

7. Pulmonary Fibrosis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pulmonary Fibrosis Discontinued Products

13. Pulmonary Fibrosis Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Pulmonary Fibrosis Key Companies

15. Pulmonary Fibrosis Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Pulmonary Fibrosis Unmet Needs

18. Pulmonary Fibrosis Future Perspectives

19. Pulmonary Fibrosis Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll